Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Cerenome, Inc. Common Stock

CNSY

Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

Last trade $0.6196
Day change -$0.0952 (-13.32%)
Day range $0.604 – $0.74
Volume 201,096
Market cap $7M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.94M
Price / earnings
—
Price / book
-7.52×
Price / sales
1.97×
EV / sales
2.81×
EV / EBITDA
-0.34×

Profitability

Earnings per share
-$3.10
Return on assets
-248.54%
Return on equity
3,285.16%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-4.17×
Current ratio
0.61×
Quick ratio
0.6×
Cash ratio
0.07×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$28.7M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CNSY, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026
Revenue$722K
Cost of revenue$912K
Gross profit-$190K
Selling, general and administrative$5.16M
Research and development$2.11M
Total operating expenses$7.27M
Operating income-$7.46M
Interest expense-$1.63M
Income before taxes-$8.66M
Income taxes$0
Net income-$8.66M
Net income attributable to common shareholders-$8.66M
EBITDA-$7.31M
Basic earnings per share-$1.14
Diluted earnings per share-$1.14

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates

Cerenome (CNSY) reported a quarterly loss of $1.14 per share, missing the consensus estimate of $0.98 loss by 16.33%. While revenues of $0.72 million beat estimates by 44.40%, they declined significantly from $1.4 million year-ago. The stock has plummeted 94% since the beginning of 2026 versus the S&P 500's 10.9% gain. Zacks assigned the stock a Hold rating (Rank #3) with mixed estimate revisions ahead.

GlobeNewswire Inc.

Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress

Cerenome (Nasdaq: CNSY) reported Q3 2026 results with $0.7M in net diagnostic revenue from its CNSide CSF assay platform. The company expanded payer coverage to ~190M covered lives including new agreements with Aetna, Medical Mutual, and others. REYOBIQ therapeutic program advanced with completed Phase 2 enrollment in recurrent glioblastoma and positive interim Phase 1 multi-dose data in leptomeningeal metastases showing no dose-limiting toxicities. However, the company reported a net loss of $8.7M and cash position of $4.9M as of September 30, 2026.

GlobeNewswire Inc.

Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO

Four biotechnology companies presented clinical findings and emerging treatment approaches for brain cancers at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. NeOnc Technologies is preparing for FDA meetings on two programs (NEO100 and NEO212), Cerenome is advancing REYOBIQ therapy and diagnostic tools, Nuvation Bio is expanding data on safusidenib for IDH1-mutant gliomas, and Jazz Pharmaceuticals is progressing dordaviprone through Phase 3 trials for rare brain cancers.

Zacks Investment Research

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

AbCellera Biologics reported a Q3 loss of $0.13 per share, beating consensus estimates of $0.18 loss by 27.78%. Revenue of $10.64 million surpassed estimates by 95.79%, up from $8.95 million year-over-year. The stock has gained 247.4% year-to-date. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

Humana (HUM) Reports Q3 Loss, Beats Revenue Estimates

Humana reported a quarterly loss of $0.7 per share, beating consensus estimates of $1.03 loss by 32.04%. The health insurer posted revenues of $40.83 billion, surpassing estimates by 0.90%, and has outperformed the S&P 500 by 60.8% year-to-date. The company received a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 2, 20261-for-25reverse split